CVMP recommendations on limited market classification and eligibility for authorisation under Article 23
List of medicines currently in PRIME scheme
Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 9-12 October 2023
Variations requiring assessment (veterinary medicines)
Opinion/decision on a Paediatric investigation plan (PIP): Resmetirom, decision type: , therapeutic area: , PIP number: P/0462/2022
Human medicines European public assessment report (EPAR): Revlimid, lenalidomide, Multiple Myeloma;Lymphoma, Mantle-Cell;Myelodysplastic Syndromes, Date of authorisation: 14/06/2007, Revision: 51, Status: Authorised
Focus group on veterinary pharmacovigilance reporting in aquaculture, European Medicines Agency, 10:00 - 17:00 Amsterdam time (CEST), from 22/11/2023 to 22/11/2023
Focus group meeting for veterinarians or other healthcare professionals on facilitating pharmacovigilance reporting of medicinal products used in aquaculture, European Medicines Agency, 10:00 - 17:00 Amsterdam time (CEST), from 22/11/2023 to 22/11/2023
Opinion/decision on a Paediatric investigation plan (PIP): Tislelizumab, decision type: , therapeutic area: , PIP number: P/0142/2019
Human medicines European public assessment report (EPAR): Fintepla, fenfluramine, Epilepsies, Myoclonic, Date of authorisation: 18/12/2020, Revision: 7, Status: Authorised